Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Multi-center Study of PIT565 in Patients With Relapsed and/or Refractory B-cell Malignancies

NCT05397496 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05397496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05397496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Multi-center Study of PIT565 in Patients With Relapsed and/or Refractory B-cell Malignancies
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 3, 2022
Completion date
January 4, 2027
Enrollment
61 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia (b-all), b-cell non-hodgkin lymphoma (b-nhl)